Skip to main content

Advertisement

Table 1 Sociodemographic and clinical patient characteristics*

From: Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract

   Adjuvant CT n=23 1stline pall n=65 2ndline pall n=29 3rd+ line pall n=8 p
Age mean (SD) 66.6 (8.2) 66.9 (10.0) 64.5 (10.8) 60.9 (14.6) 0.370
Sex men 34.8% 52.3% 65.5% 50.0% 0.182
  women 65.2% 47.7% 34.5% 50.0%  
Diagnosis pancreatic cancer 78.3% 72.3% 75.9% 87.5% 0.786
  gall cancer 21.7% 27.7% 24.1% 12.5%  
Time since diagnosis§ mean (SD) 3.4 (5.0) 3.5 (4.5) 11.1 (7.5) 24.8 (8.1) <0.001
Metastasis yes 17.4% 48.3% 62.1% 87.5% 0.001
  no 82.6% 51.7% 37.9% 12.5%  
Previous Surgery yes 100.0% 58.9% 70.4% 71.4% 0.004
  no 0.0% 41.1% 29.6% 28.6%  
Chemotherapy regimen Gemcitabine Mono 90.9% 40.6% 6.9% 0.0% <0.001
  Gemcitabine Combination Therapy 9.1% 45.3% 27.6% 25.0%  
  FOLFIRINOX 0.0% 4.7% 0.0% 0.0%  
  FOLFOX/XELOX 0.0% 9.4% 55.2% 37.5%  
  FOLFIRI 0.0% 0.0% 3.4% 12.5%  
  Other 0.0% 0.0% 6.9% 25.0%  
  1. Total N = 80, whereas 36 patients were accounted for two, six patients for three and three patients for three or more chemotherapy lines because they passed from one line to another.
  2. § Number of months that passed since diagnosis, averaged across all assessments within a chemotherapy line.